World Tb Day Symposium 2026 Playbook
Written by Neilay Bhalerao
Good morning. This is your synopsis for World Tb Day Symposium Organised by UCL-TB/LSHTM 2026 in Kennedy Lecture Theatre, 30 Guilford Street, London.
DRIVING THE DAY
TB’S UNFINISHED BUSINESS: If anyone thought Tuberculosis was yesterday’s problem, this week’s World TB Day Symposium 2026 had a different idea.
Researchers, funders and policymakers gathered at UCL’s Kennedy Lecture Theatre and delivered a message that was equal parts familiar and uncomfortable. The world knows how to tackle TB. It is just not doing it fast enough.
THE GAP: Not knowledge. Not tools. Execution.
THE MOOD IN THE ROOM
PROGRESS, BUT PATCHY: There was no shortage of good news if you looked hard enough.
Shorter treatments. Better diagnostics. Vaccine candidates moving through the pipeline.
Then came the reality check. None of it is reaching enough people.
POST COVID SHADOW: The legacy of COVID-19 hung over almost every session. Missed diagnoses. Interrupted care. Health systems still catching up.
One speaker summed it up neatly. TB did not pause for the pandemic. The response did. No active case finding in UK.
FOLLOW THE MONEY
SHOW ME THE FUNDING: The numbers did not get softer with repetition.
Global TB financing is still falling short of targets set by the World Health Organization. Donor fatigue is real. Domestic budgets are stretched. TB is competing with everything from conflict to climate.
And don’t even get me started on the effects summarised by various researchers about Climate change and conflict on Tuberculosis
THE NEW PITCH: Forget just saving lives. Start talking economics.
Speakers leaned heavily into cost effectiveness and affordability. Invest now, save later. Ignore TB, and the bill comes due with interest.
POLICY PLAYBOOK
INTEGRATE OR FAIL: One of the clearest lines of consensus.
TB cannot sit in its own silo anymore. The future is integration with primary care, HIV services and broader health security systems.
DATA DEFICIT: Another familiar headache.
Weak surveillance means blind spots. Blind spots mean missed cases. Missed cases mean continued transmission.
Translation for policymakers. You cannot fix what you cannot see.
GLOBAL SNAPSHOT
NOT JUST “OVER THERE”: Yes, high burden countries like India and South Africa remain central. But speakers pushed back on the idea that TB is someone else’s problem.
Urban inequality. Migration. Fragile health systems. All keeping transmission alive across regions, including closer to home.
GROWING PROBLEM The exclusionary politics of care towards the migrant population could be a looming new fork in the road in HICs, which needs to be carefully treaded
DRUG RESISTANCE WARNING: Multidrug resistant TB got its own share of alarm bells.
More complex. More expensive. Harder to treat. A slow burn crisis within the broader epidemic.
WHAT STUCK
THE VACCINE QUESTION: Plenty of cautious optimism. No silver bullet YET to replace the BCG vaccine.
THE DELIVERY PROBLEM: Tools exist. Access does not.
THE ECONOMIC TURN: The case for action is now being framed in pounds and dollars, not just lives.
BOTTOM LINE
THE ACTION GAP STRIKES AGAIN: By the end of the day, the consensus was hard to ignore.
TB is preventable. Treatable. Curable.
And still killing on a massive scale.
Not because science failed. Because systems did.
ONE LINE TO TAKE AWAY
As one participant put it, “We are choosing, collectively, to move too slowly.”
Keep watching this space. TB may not lead the news cycle, but it is quietly testing whether global health promises actually mean anything.
BEYOND M25 LINK UP
As per tradition did a USCF-UCL/LSHTM link up across the pond was fun to watch and learn problems over in chaos land, in these trying times it’s good to band together and keep the hope alive!
Thank you to everyone who participated, it was great coming across so many amazing minds.
